Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
QNCX Stock Forecast 2025-2026
$4.01
Current Price
$223.28M
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to QNCX Price Targets
+149.4%
To High Target of $10.00
+99.5%
To Median Target of $8.00
-0.2%
To Low Target of $4.00
QNCX Price Momentum
+26.5%
1 Week Change
+157.1%
1 Month Change
+91.0%
1 Year Change
+114.4%
Year-to-Date Change
-6.7%
From 52W High of $4.30
+456.9%
From 52W Low of $0.72
📊 TOP ANALYST CALLS
Did QNCX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Quince Therapeutics is one of their latest high-conviction picks.
Latest QNCX Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, QNCX has a bullish consensus with a median price target of $8.00 (ranging from $4.00 to $10.00). The overall analyst rating is N/A (N/A/10). Currently trading at $4.01, the median forecast implies a 99.5% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Leland Gershell at Oppenheimer, projecting a 149.4% upside. Conversely, the most conservative target is provided by Jason Kolbert at D. Boral Capital, suggesting a 0.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
QNCX Analyst Ratings
6
Buy
0
Hold
0
Sell
QNCX Price Target Range
Low
$4.00
Average
$8.00
High
$10.00
Current: $4.01
Latest QNCX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for QNCX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 13, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $4.00 |
| Sep 26, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $4.00 |
| Aug 15, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $4.00 |
| Aug 12, 2025 | JMP Securities | Jonathan Wolleben | Market Outperform | Maintains | $8.00 |
| Aug 5, 2025 | JMP Securities | Jonathan Wolleben | Market Outperform | Initiates | $9.00 |
| Jul 17, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $4.00 |
| Jun 13, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $4.00 |
| Jun 4, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $4.00 |
| Mar 25, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $4.00 |
| Mar 24, 2025 | Oppenheimer | Leland Gershell | Outperform | Initiates | $10.00 |
| Feb 5, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $12.00 |
| Jan 2, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $12.00 |
| Dec 18, 2024 | Brookline Capital | Buy | Initiates | $N/A | |
| Nov 14, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $12.00 |
| Nov 12, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $12.00 |
| Nov 7, 2024 | Maxim Group | Jason McCarthy | Buy | Initiates | $6.00 |
| Oct 29, 2024 | Rodman & Renshaw | Elemer Piros | Buy | Initiates | $11.00 |
| Oct 22, 2024 | EF Hutton | Jason Kolbert | Buy | Initiates | $12.00 |
| May 11, 2022 | Credit Suisse | Underperform | Maintains | $N/A | |
| Mar 9, 2022 | HC Wainwright & Co. | Buy | Maintains | $N/A |
Quince Therapeutics, Inc. (QNCX) Competitors
The following stocks are similar to Quince Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
QNCX
Quince Therapeutics
mkt cap
223.28M
Quince Therapeutics, Inc. (QNCX) Financial Data
Quince Therapeutics, Inc. has a market capitalization of $223.28M with a P/E ratio of -2.8x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -247.8%.
Valuation Metrics
Market Cap
$223.28M
Enterprise Value
$214.99M
P/E Ratio
-2.8x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+11.8%
Current Ratio
1.1x
Debt/Equity
1,699.1x
ROE
-247.8%
ROA
-22.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Quince Therapeutics, Inc. (QNCX) Business Model
About Quince Therapeutics, Inc.
What They Do
Biotechnology company developing innovative therapies.
Business Model
Quince Therapeutics focuses on discovering and developing therapies for medical conditions with significant unmet needs, particularly in rare diseases. The company generates revenue through strategic partnerships and collaborations, translating scientific breakthroughs into practical solutions for patients.
Additional Information
The company is committed to advancing healthcare through its R&D initiatives, aiming to improve patient outcomes and quality of life. As a player in the pharmaceutical and biotechnology sector, Quince Therapeutics is engaged in bringing novel therapeutics from concept to clinical reality.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
36
CEO
Dr. Dirk Thye M.D.
Country
United States
IPO Year
2019
Website
www.quincetx.comQuince Therapeutics, Inc. (QNCX) Latest News & Analysis
Latest News
Quick Summary
Quince Therapeutics (Nasdaq: QNCX) will have senior management, including CEO Dirk Thye, present at the Piper Sandler Healthcare Conference on December 3, 2025.
Why It Matters
Quince Therapeutics' participation in key investor events signals confidence in its strategies and potential, which could attract investment interest and impact stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
26 days ago
Quick Summary
Quince Therapeutics (Nasdaq: QNCX) updated its development pipeline and reported Q3 financial results for the period ending September 30, 2025, indicating progress in their rare disease treatments.
Why It Matters
Quince Therapeutics' pipeline update and financial results could influence stock performance and investor sentiment, particularly regarding its potential in treating rare diseases.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Quince Therapeutics (Nasdaq: QNCX) reported positive results from a pre-planned safety analysis by an independent board for its Phase 3 NEAT clinical trial targeting rare diseases.
Why It Matters
Positive safety analysis results for Quince Therapeutics' Phase 3 trial can boost investor confidence, potentially leading to increased stock value and interest in the biotech sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Quince Therapeutics (Nasdaq: QNCX) presented data on walking capacity in children with Ataxia-Telangiectasia at the CNS Annual Meeting, focusing on age-related capacity loss.
Why It Matters
Quince Therapeutics' data presentation on walking capacity in A-T patients highlights potential advancements in rare disease treatment, which could attract investor interest and impact stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Quince Therapeutics will hold its first Analyst/Investor Day on October 2, 2025, at 10:00 AM EDT, featuring key executives including CEO Dirk Thye and other company leaders.
Why It Matters
Quince Therapeutics' first Investor Day signals a commitment to transparency and engagement, potentially boosting investor confidence and interest in the company's future prospects.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quince Therapeutics, Inc. - Special Call
2 months ago
Quick Summary
Quince Therapeutics held a special conference call featuring CEO Dirk Thye and COO Brendan Hannah, with participation from H.C. Wainwright analyst Andrew Fein.
Why It Matters
Quince Therapeutics' conference call indicates potential updates on strategy and financial performance, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About QNCX Stock
What is Quince Therapeutics, Inc.'s (QNCX) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, Quince Therapeutics, Inc. (QNCX) has a median price target of $8.00. The highest price target is $10.00 and the lowest is $4.00.
Is QNCX stock a good investment in 2026?
According to current analyst ratings, QNCX has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.01. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for QNCX stock?
Wall Street analysts predict QNCX stock could reach $8.00 in the next 12 months. This represents a 99.5% increase from the current price of $4.01. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Quince Therapeutics, Inc.'s business model?
Quince Therapeutics focuses on discovering and developing therapies for medical conditions with significant unmet needs, particularly in rare diseases. The company generates revenue through strategic partnerships and collaborations, translating scientific breakthroughs into practical solutions for patients.
What is the highest forecasted price for QNCX Quince Therapeutics, Inc.?
The highest price target for QNCX is $10.00 from Leland Gershell at Oppenheimer, which represents a 149.4% increase from the current price of $4.01.
What is the lowest forecasted price for QNCX Quince Therapeutics, Inc.?
The lowest price target for QNCX is $4.00 from Jason Kolbert at D. Boral Capital, which represents a -0.2% decrease from the current price of $4.01.
What is the overall QNCX consensus from analysts for Quince Therapeutics, Inc.?
The overall analyst consensus for QNCX is bullish. Out of 6 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are QNCX stock price projections?
Stock price projections, including those for Quince Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 8, 2025 5:08 PM UTC